Treatment characteristics and the risk of inhibitor development: a multicenter cohort study among previously untreated patients with severe hemophilia A.
about
Alloantibodies to therapeutic factor VIII in hemophilia A: the role of von Willebrand factor in regulating factor VIII immunogenicityDangerous liaisons: how the immune system deals with factor VIIIFVIII inhibitors: pathogenesis and avoidanceDifferent impact of factor VIII products on inhibitor development?Validity of assessing inhibitor development in haemophilia PUPs using registry data: the EUHASS project.Factor VIII brand and the incidence of factor VIII inhibitors in previously untreated UK children with severe hemophilia A, 2000-2011The IL-10 polarized cytokine pattern in innate and adaptive immunity cells contribute to the development of FVIII inhibitors.Design of the INHIBIT trial: preventing inhibitors by avoiding 'danger', prolonging half-life and promoting tolerance.Treatment of hemophilia: a review of current advances and ongoing issuesChallenges and successes in the treatment of hemophilia: the story of a patient with severe hemophilia A and high-titer inhibitors.The immunogenicity of platelet-derived FVIII in hemophilia A mice with or without preexisting anti-FVIII immunitySyngeneic transplantation of hematopoietic stem cells that are genetically modified to express factor VIII in platelets restores hemostasis to hemophilia A mice with preexisting FVIII immunityPlatelet gene therapy corrects the hemophilic phenotype in immunocompromised hemophilia A mice transplanted with genetically manipulated human cord blood stem cells.Optimal use of recombinant factor VIIa in the control of bleeding episodes in hemophilic patients.Clinical advances in hemophilia management.Surgery and inhibitor development in hemophilia A: a systematic review.The literature on inhibitors: articles that influence my management of patients with hemophilia A and high-titer inhibitors.Octocog alfa, antihaemophilic factor (recombinant), plasma/albumin free method (Advate®): a review of its use in the management of patients with haemophilia A.How we use recombinant activated Factor VII in patients with haemophilia A or B complicated by inhibitors. Working group of hematology experts from Australia and New Zealand, Melbourne, April 2011.Alloantibodies in previously untreated hemophilia A patients: the role of environmental factors.Factor VIII inhibitors in hemophilia A: rationale and latest evidenceBlood Clotting Factor VIII: From Evolution to Therapy.The role of previously untreated patient studies in understanding the development of FVIII inhibitors.A close insight to factor VIII inhibitor in the congenital hemophilia A.Non-genetic risk factors in haemophilia A inhibitor management - the danger theory and the use of animal models.Treatment burden, haemostatic strategies and real world inhibitor screening practice in non-severe haemophilia A.The EPIC study: a lesson to learn.Real-life evidence in evaluating effectiveness of treatment in Haemophilia A with a recombinant FVIII concentrate: a non-interventional study in emerging countries.Genetic determinants of immunogenicity to factor IX during the treatment of haemophilia B.Modification of an exposed loop in the C1 domain reduces immune responses to factor VIII in hemophilia A mice.Discontinuous epitopes on the C2 domain of coagulation Factor VIII mapped by computer-designed synthetic peptides.Haemophilia in the first years of life.Physical and mental quality of life in adult patients with haemophilia in Belgium: the impact of financial issues.Diagnosis and treatment of factor VIII and IX inhibitors in congenital haemophilia: (4th edition). UK Haemophilia Centre Doctors Organization.Treatment related factors and inhibitor development in children with severe haemophilia A.Recombinant factor concentrates may increase inhibitor development: a single centre cohort study.Improved prediction of inhibitor development in previously untreated patients with severe haemophilia A.Von Willebrand factor in high-purity factor VIII complex concentrates: chaperone protein or key to therapies? A meeting report.Risk of inhibitor development in mild haemophilia A increases with age.Continuous infusion in haemophilia: current practice in Europe.
P2860
Q26866323-BE5601AD-59C2-492D-B275-880BDCBCA415Q27000818-9C1F503B-B6C1-444E-AE16-BFF1952C0CA3Q27027224-923B886F-CCA4-4E35-8B37-C0A81A2BE804Q28075679-C3A47DAC-2142-47DD-B9EE-1983EC101353Q34063824-D279D913-3592-459D-A41A-9DD4ECDE07BBQ34580100-BCE945B1-F74A-469F-AA57-2D6DC84B6814Q35046770-16E14373-6E3D-4C03-87CB-F94A5E387F80Q35168244-FACC5395-A404-40DC-BB1D-D7C7A577B468Q35683781-9C060F7D-14AC-446A-B8BD-54A434D525C5Q36019034-F3547827-D1B8-493E-AC75-00B28EE0F30DQ36675079-C783A5DE-DD30-4018-BB77-307FC43D26ECQ36915859-951BC5E0-2EBD-4DB5-AF34-2AECCE24B7F2Q37489033-C484F547-B7FC-4550-A2F9-C64072BBFC9CQ37778292-B1C8BAA4-A4CA-47AD-B40C-7B2C799287D0Q37900933-0E80FAFF-4628-49AB-B2BC-FCCF6F97DD39Q37916686-E84B4FDB-A40E-4F39-9FA4-22F47774C0A4Q37999694-7443C024-709E-435F-8ADE-601034596CEFQ38008021-87B7539D-5852-4B25-8CD3-B85162F5D3E7Q38060224-53CAE07B-32D6-4E68-9CF2-8DD26A4917D0Q38080144-A343CDA8-D543-4F44-8532-A2F9F4051849Q38101041-001E1AE3-4785-4CC4-AA60-7FFBD14286FBQ38118763-31AD6419-07B2-45FE-AAB5-E4A826E85B2AQ38575475-0CB368D4-2F61-4FAE-92F9-EA95C0CDA112Q38883211-0A2DAABA-EF4D-4F34-B18D-F6E158B84DE5Q38937408-817D6C93-6705-4393-AC09-985994E7A0E8Q38960476-1FC48FD0-61C8-4ECE-87E5-E3B39AC0376FQ41014168-22978C91-9EAE-44AC-B775-E18AD177893FQ41504794-F596580C-F154-4ACD-A551-320AE55B97C7Q41732261-BFF1C53D-F589-4FB3-8E22-41223E4EEE35Q42096639-46032907-C3A2-4A37-90F8-9EABA621AF2AQ44140043-1D486570-DC38-4291-9876-12F0DF430F0DQ44263772-42EC0F57-4D2B-42DA-8360-DBA00265BA6FQ44265093-1FB72CF9-F4EF-44C8-B75F-2BBC948F355DQ45838031-19A79141-2F1C-437C-A892-060DC0705424Q45864946-20CC4A4B-87D6-498B-98BE-93C6A5B26518Q45866892-C84EFDE6-7DE2-47FD-A40B-739E68B76696Q45871101-A462702F-1DEE-4C49-83E6-C40F0C453B84Q45871996-B5BA8DCA-8EF0-4546-AC9A-D73C86496487Q45872598-DD28377D-D87A-468F-A644-BD5629A1CBEFQ45878760-E2460C5F-5E71-40F7-9D00-56D8122C1E07
P2860
Treatment characteristics and the risk of inhibitor development: a multicenter cohort study among previously untreated patients with severe hemophilia A.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh-hant
name
Treatment characteristics and ...... ents with severe hemophilia A.
@en
Treatment characteristics and ...... ents with severe hemophilia A.
@nl
type
label
Treatment characteristics and ...... ents with severe hemophilia A.
@en
Treatment characteristics and ...... ents with severe hemophilia A.
@nl
prefLabel
Treatment characteristics and ...... ents with severe hemophilia A.
@en
Treatment characteristics and ...... ents with severe hemophilia A.
@nl
P2860
P921
P1476
Treatment characteristics and ...... ients with severe hemophilia A
@en
P2093
van den Berg HM
P2860
P304
P356
10.1111/J.1538-7836.2007.02595.X
P577
2007-04-20T00:00:00Z